Insulet (PODD)
(Delayed Data from NSDQ)
$229.94 USD
-0.05 (-0.02%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $229.85 -0.09 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum C VGM
Price, Consensus and EPS Surprise
PODD 229.94 -0.05(-0.02%)
Will PODD be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for PODD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PODD
HLN or PODD: Which Is the Better Value Stock Right Now?
BAX vs. PODD: Which Stock Should Value Investors Buy Now?
PODD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Continue to Retain PODD Stock in Your Portfolio Now?
Insulet's Omnipod 5 Wins FDA Approval for Type 2 Diabetes
Illumina (ILMN) Beats on Q2 Earnings, Lowers 2024 Sales View
Other News for PODD
Medtronic issues recall for MiniMed insulin pumps over battery issues
Insulet price target raised by $25 at Citi, here's why
BDX upped to buy by Citi, TNDM put on Negative Catalyst Watch
Insulet to Announce Third Quarter 2024 Financial Results on November 7, 2024
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday